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The phospholipid bilayer is a highly dynamic structure. Approximately 2% is recycled every 5 
to 10 minutes, so the whole membrane is recycled every one to two hours. The process 
involves constant formation of endosomes that bud off by endocytosis from the plasma 
membrane and become internalised into the cytoplasm. These endosomes, together with 
their associated intra-membranous proteins, represent a snapshot of that cell’s plasma 
membrane composition. Further rounds of endocytosis within the endosomes themselves 
generate intracellular multivesicular bodies. Upon fusing with the plasma membrane, these 
endosomes release their contents into the circulation (they were first identified in the 
maturing mammalian reticulocyte) or, in the case of renal tubular epithelial cells, into the 
urine. The resultant urinary ‘exosome’ may be characterised by their size (generally 
between 20-100 nm) and density (1.10-1.19 g/ml). They are representative of the plasma 
membrane from which they originated and therefore offer a potential window into the 
pathophysiology of the kidney, providing information about changes in membrane or 
cytosolic composition from specific segments of the nephron.  
 
Chronic kidney disease (CKD) is highly prevalent and is expected to increase further in the 
next 5-10 years because of the rising prevalence of obesity and diabetes. Acute kidney injury 
(AKI), the loss of kidney function over hours to days, is also very common, being seen in up 
to 20% of acute hospital admissions. There are often delays in detection of both AKI and 
CKD, which can lead to worse clinical outcomes. The use of urinary biomarkers is key to the 
early detection of kidney disease (and also to some systemic conditions that might lead to 
changes in renal epithelial composition). Urine is an excellent fluid for biomarker discovery 
and development, having sufficient quantities of measureable peptides and/or proteins and 
being relatively easy to non-invasively obtain in reasonable quantities (assuming the patient 
is not oligouric). Hence, some urinary biomarkers such as albumin:creatinine ratio (ACR) are 
already used in routine clinical practice. Detection of increased ACR might, for example, be 
the first sign of diabetic nephropathy. AKI is currently defined by an increase in serum 
creatinine or a fall in urine output, but these changes can occur relatively late with respect 
to the renal injury, potentially leading to delays in treatment. Urinary biomarkers such as 
neutrophil gelatinase associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1) have 
shown promise as novel early biomarkers of AKI. Biomarker discovery and development is 
an active field of basic and clinical research. More detailed examination of the urinary 
proteome, including analysis of exosomes, creates further opportunity for discovery of 
clinically useful early biomarkers of disease. Putative exosomal biomarkers of AKI have been 
reported, such as the Na+/H+ exchanger isoform 3 (NHE3) (du Cheyron et al., 2003) and 
Fetuin-A (Zhou et al., 2006) but with improved technology for exosome analysis, more 
sensitive and specific biomarkers might be discovered. 
  
To date, the difficulty with determining and quantifying urinary exosomes has been their 
lability, small size and particular density.  Accurate and reproducible identification has been 
labour intensive, expensive and has required specific laboratory equipment and skills (for 
example, Western blotting). A new study published in the current issue of the Journal 
suggests a novel approach that may change this situation. Using nanoparticle tracking 
analysis (NTA) Oosthuyzen et al successfully identified a range of particle sizes in urine, 
including those classified typically as exosomes. They validated the technique by 
fluorescently tagging known exosomal proteins such as CD24 (a cell surface marker) and 
aquaporin 2 (AQP2) and co-localising their fluorescent read-out in the range of particle sizes 
typically defining exosomes (20-100nm). They prospectively identified an increase in the 
output of urinary exosomes tagged with AQP2 under known stimulatory conditions 
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(treatment with the arginine vasopressin analogue, desmopressin). The authors conducted 
their studies in a cell line, then in an animal model and finally in 5 healthy volunteers and a 
patient with central diabetes insipidus treated with desmopressin.  The authors also 
established optimal conditions for urine storage for potential use in biomarker discovery 
studies using NTA. So what exactly is NTA? 
 
NTA was invented in the UK by Dr Bob Carr who subsequently founded Nanosight Ltd 
(http://www.nanosight.com/) in 2003. NTA is used to observe (in conjunction with a high-
powered microscope) and analyse (using specialised software) particle movement within a 
solution. The rate of movement of these particles (Brownian motion) is determined by a 
number of factors including, particle size, viscosity and temperature of the liquid but is not 
affected by particle density or refractive index. Thus, using NTA, a size distribution profile of 
small (10-1000 nm) particles in solution (e.g. urine) can be produced with minimal sample 
preparation and hence time associated with the procedure. With further development, 
refinements and validation it is possible in time that the analysis may be done in real-time 
with no preparation. However, given the complexity of the equipment required, a simple 
point of care (‘bedside’) test would appear to be some time off. Nevertheless, by elucidating 
optimal handling of samples for NTA analysis of urinary exosomes, the authors have 
contributed to bringing this exciting technique a step closer to routine clinical use. No doubt 
researchers in acute and chronic kidney disease, interested in identification of disease 
biomarkers, will take note. 
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